UNSPSC 51284902: Aztreonam/dextrose

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM119. This VA Drug Class (AM119) classifies this compound as belonging to the group BETA-LACTAMS ANTIMICROBIALS, OTHER.

UNSPSC 51284902 Aztreonam/dextrose is a Commodity code representing pharmaceutical products, but recent state and local solicitations tagged under this code are not actually purchasing aztreonam or dextrose-based medications. Instead, the opportunities show demand for emergency medical supplies, naloxone, drug deactivation systems, generic pharmaceuticals, and over-the-counter products across public health agencies, fire rescue divisions, and state pharmacy programs. The issuing bodies include county health departments, municipal fire departments, state health and human services commissions, and cooperative purchasing alliances serving multiple state and local jurisdictions. The work being solicited ranges from direct pharmaceutical supply contracts with quarterly or ongoing delivery schedules to preliminary market-intelligence gathering for direct-to-manufacturer pharmacy programs.

Recent activity appears concentrated in Florida, Texas, and Minnesota. Seminole County, Florida released an IFB on June 30, 2026 (due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with a two-year initial term and one-year renewal option. The City of Tampa issued an IFB on March 25, 2026 (due March 13, 2026) for 169 line items of medical and first aid supplies including respiratory equipment, cardiac monitoring electrodes, and consumables for the Fire Department Rescue Division, with an estimated contract value of $700,000, designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount. The Texas Health and Human Services Commission posted an RFI on April 3, 2026 to gather vendor capabilities regarding a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP due March 26, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with awards effective July 1, 2026 and a contract term of two years. The code shows little direct activity in aztreonam/dextrose itself; the tagging mismatch suggests opportunities are being classified under this code by error or overly broad categorization.